-
Founded in:
2000-10-20 -
Country:
China -
Address:
Chenglinzhuang Industrial Zone, Tianjin -
Tax NO.:
91120110103738323L -
Registered Funds:
- -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ticlopidine hydrochloride |
Antiplatelet aggregation drugs can inhibit platelet aggregation caused by various inducers such as ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides, and can inhibit platelet aggregation reactions induced by exogenous and endogenous ADP.
More
Antiplatelet aggregation drugs can inhibit platelet aggregation caused by various inducers such as ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides, and can inhibit platelet aggregation reactions induced by exogenous and endogenous ADP. |
53885-35-1 | 22 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Tiapride hydrochloride |
Extract from the above information
More
Extract from the above information |
51012-33-0 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
This product is a hypoglycemic drug. Its pharmacological effects include: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes.
More
This product is a hypoglycemic drug. Its pharmacological effects include: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 5. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes. |
15537-72-1 | 55 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
This product is a hypoglycemic drug. It can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. Its hypoglycemic mechanism may be: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 7. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike the effect of insulin, this product has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people, but has a good therapeutic effect on type 2 diabetes.
More
This product is a hypoglycemic drug. It can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and HbAlc can be reduced by 1% to 2%. Its hypoglycemic mechanism may be: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose; 7. Inhibit the biosynthesis and storage of cholesterol and reduce blood triglyceride and total cholesterol levels. Unlike the effect of insulin, this product has no effect on promoting fat synthesis and no obvious hypoglycemic effect on normal people, but has a good therapeutic effect on type 2 diabetes. |
15537-72-1 | 55 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Alginic Sodium Diester |
It has many functions, such as improving the viscoelasticity of blood rheology, anti-coagulation, anti-thrombosis, lowering blood viscosity, relieving spasm of micro-arteries and veins, disaggregation of red blood cells and platelets, lowering blood lipids, inhibiting atherosclerosis, dilating peripheral blood vessels, improving microcirculation, inhibiting arteriovenous thrombosis, lowering blood sugar and blood pressure.
More
It has many functions, such as improving the viscoelasticity of blood rheology, anti-coagulation, anti-thrombosis, lowering blood viscosity, relieving spasm of micro-arteries and veins, disaggregation of red blood cells and platelets, lowering blood lipids, inhibiting atherosclerosis, dilating peripheral blood vessels, improving microcirculation, inhibiting arteriovenous thrombosis, lowering blood sugar and blood pressure. |
9005-40-7 | 11 |